|Stage of funding:||Completed|
Founded in 2006 and located in Sunnyvale, California, Miramar Labs is a privately-owned medical device company dedicated to launching the next generation energy modality to treat dermatologic medical conditions.
Miramar Labs is the tenth company created by The Foundry, a leading medical device incubator based in Menlo Park, California.
Supported by rigorous clinical research, Miramar Labs is focused on addressing dermatologic medical conditions for which there are significant unmet clinical needs. Miramar Labs is excited to have developed its miraWave technology™, a breakthrough technology platform using microwave energy. Used for treatment in other medical areas such as oncology, cardiology and urology, microwave energy is well-positioned to be adopted for dermatologic conditions.
The first priority is the treatment of excessive axillary hyperhidrosis, a medical condition that significantly affects the quality of life of tens of millions of people. The miraDry procedure uses microwave energy to provide a non-invasive, lasting solution to axillary hyperhidrosis. The miraDry System available in North America, Europe and Asia Pacific for the treatment of primary axillary hyperhidrosis.
Miramar Labs, Inc. (OTCQB: MRLB) was acquired by Sientra, Inc. (NASDAQ: SIEN) in July 2017.
Clearside Biomedical, Inc. (“Clearside”), (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that data from PEACHTREE, its pivotal Phase 3 trial of suprachoroidal CLS-TA in patients with macular edema associated with non-infectious uveitis, will be shared as a late-breaking oral presentation during the 2018 annual meeting of the American Society of Retina Specialists , July 20-25 in Vancouver, Canada .
11 July 2018
10 July 2018
21 June 2018